Disclosure statement: CAP, DK, JHS are consultants to BMS. SP is on the SAB of Abpro inc. ASP is co-founder, co-chair Scientific Advisory Board of Cabaletta Bio. All other authors have declared that no conflict of interest exists.
Introduction
Systemic sclerosis (SSc) is a systemic autoimmune inflammatory disorder of unknown etiology characterized by prominent fibrosis that may affect many organs including the skin, lungs, kidneys, and gastrointestinal tract (1) . Another important feature of this disease is vasculopathy that leads to vasospasm, pulmonary arterial remodeling, and microvascular obliteration (1) (2) (3) (4) . SSc is progressive, highly morbid, and in its most severe form, carries a mortality rate comparable to the most fatal metastatic cancers (5) . Current treatment paradigms slow fibrosis but do not halt or reverse it. True disease regression has only consistently been observed following autologous stem cell transplantation (6) (7) (8) (9) . The therapeutic efficacy of stem cell transplantation supports the notion that SSc is driven by an aberrant immune response and that the disease process can be reversed. Our imprecise understanding of the immune mechanisms that drive SSc likely contributes to the difficulty in identifying effective therapeutics in this disease.
T cells are present in SSc tissues and have been postulated to drive both the endothelial dysfunction and the fibrotic pathology of this disease, presumably via the secretion of cytokines that eventually contribute to the activation of macrophages, fibroblasts and myofibroblasts (10) .
The latter two cell types, fibroblasts and myofibroblasts, secrete type I collagens and matrix metalloproteinases such as MMP-9 and MMP-12, and the process of dysregulated wound healing could contribute to the fibrosis seen in this disease. Whether fibrosis is a consequence of parenchymal cell death and tissue remodeling or results primarily from the cytokines within an inflammatory milieu is unclear. These mechanisms are not mutually exclusive, however, and could even be sequential.
In SSc, T H2 cells, T H17 cells, T H1 cells, T H22 cells, regulatory T cells, T follicular helper
(T FH ) cells and CD8+ T cells have all been implicated in the pathogenic process (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
However, no previous studies have used quantitative approaches to enumerate T cell subsets 4 within SSc lesions. There remains a paucity of information regarding the phenotype of infiltrating T cells and the precise role of T cells in the pathogenesis of this disease remains to be established. While B cells have also been associated with the pathogenesis of SSc and beneficial effects of B cell depleting therapy have been reported, the relative contributions of B and T lymphocytes have not been systematically interrogated at the tissue level (22) (23) (24) .
We chose to interrogate cytotoxic CD4+ T cells (CD4+CTLs) and other CD4+ T cell subsets in SSc tissues based on our previous blood and tissue studies on IgG4-related disease (IgG4-RD). IgG4-RD is also a chronic, immune-mediated fibrotic disorder characterized by inflammatory tumor-like masses with a predilection for the lacrimal glands, salivary glands, pancreas, bile ducts, and retroperitoneal tissues (25) . We have identified CD4+CTLs as the dominant effector CD4+ T cell subset infiltrating tissues affected by IgG4-RD along with large clonal expansions in the blood (26) (27) (28) . These cells decline in conjunction with treatmentinduced remission (26, 28) . CD4+CTLs have the potential to drive fibrosis through the elaboration of pro-fibrotic cytokines and/or by the induction of apoptosis of target cells (26) .
CD4+CTLs have been extensively studied in the setting of chronic viral infections such as CMV and HIV but there remain many gaps in our knowledge regarding these cells and their potential role in immune-mediated fibrosis (29) (30) (31) . In addition to the in-depth investigation of CD4+CTLs in IgG4-RD, these cells have also been associated with idiopathic pulmonary fibrosis and CD4+ T cells with a cytotoxic phenotype have recently been reported in the context of rheumatoid arthritis (32, 33) . Studies in healthy volunteers demonstrated heterogeneity of CD4+CTLs among effector memory T cells that had regained CD45RA expression (T EMRA ), and an IL-7 receptor expressing subset was defined as the precursor population to effector CD4+CTLs (34, 35) . Functional subsets of CD4+CTLs have, however, not been identified in the context of inflammation and human fibrotic disease. Moreover, although we had previously described CD4+CTL expansions within the blood of a relatively small number of SSc patients, the relevance of these cells to the pathogenesis of SSc has not yet been investigated rigorously, 5 and the broader relevance of CD4+CTLs to diseases other than IgG4-RD requires exploration (26) .
In our studies described here, we show that both CD4+ and CD8+ T cells accumulate in skin biopsies of untreated patients with early diffuse systemic sclerosis and outnumber infiltrating B cells. In most of these patients CD4+CTLs represent the dominant CD4+ T cell subset infiltrating the skin whereas T H1 , T H2 , T FH and regulatory T cells are relatively sparse in SSc tissues. Examination of selected patients with lower numbers of infiltrating CD4+CTLs revealed some increase in TH17 cells, but the dominant T cells in the overwhelming majority of SSc patients are cytotoxic T cells -including CD4+CTLs and effector CD8+ T cells. We catalogue the prominent apoptosis of endothelial cells, the accumulation of CD4+CTLs in the vicinity of the endothelium and the upregulation of HLA class II by endothelial cells in SSc skin biopsies, raising the possibility that CD4+CTLs may drive tissue fibrosis by contributing to the apoptotic death of specific cell types in an antigen-specific manner. In addition, CD4+CTLs elaborate pro-inflammatory and pro-fibrotic cytokines that may contribute to an over-exuberant, cytokine-driven tissue remodeling process inducing the secretion of excessive amounts of collagen, thereby compromising tissue and organ function. We further categorize an effector subset of CD4+CTLs from the blood of SSc patients, denoted by the loss of surface CD28 and gain of CD57. This population of cells shows marked clonal expansion and a highly cytotoxic profile at both the protein and transcriptional levels. We also demonstrate that the accumulation of CD4+CTLs in the skin of SSc patients can be attenuated by treatment with CTLA4-Ig, suggesting that ongoing T cell activation contributes to the pathologic alterations that are observed in this disease.
Results

CD4+CTLs and CD8+ T cells are prominent in SSc tissues
In our analyses of the adaptive immune cells infiltrating tissues affected by SSc, we simultaneously quantified the relative contribution of CD3+ T cells and CD19+ B cells in the skin of 35 patients with early diffuse SSc prior to the initiation of any immunosuppressive treatment.
While prominent numbers of both B and T cells were observed, the absolute number of infiltrating T cells was greater than those of infiltrating B cells ( Figures 1A-B ). Although randomized double-blind clinical trials examining the utility of B cell depletion therapy in SSc have not been performed, some studies have reported clinical improvement with rituximab, especially in the context of early diffuse SSc (22, 23) . Additionally, activated B cells have been observed in the circulation of SSc patients (24, 36) . While there may be a contribution of infiltrating B cells to pathology in SSc, we focused on the T cells in the infiltrate across this group of patients given their relative preponderance in the tissue.
We first examined the relative contribution of CD8+ and CD4+ T cells to the overall CD3+ T cell infiltrate. We found that CD8+ T cells and CD4+ T cells were both present in high numbers in SSc tissues with some variation in the relative abundance of each of these T lineages across patients ( Figures 1C-D) . Given the varied literature regarding CD4+ T cell subsets in the context of SSc, we directly quantified CD4+ T cell subsets in the skin across this cohort of 35 untreated patients. We initially defined CD4+CTLs by the co-expression of CD4 and GZMA and quantified their relative contribution to the total CD4+ T cell infiltrate. Consistent with our previous report of expanded CD4+CTLs in the blood of SSc patients (26) , we observed a prominent accumulation of CD4+CTLs within the affected skin of SSc patients (Figures 2A-C) .
To validate this finding, we additionally co-stained tissues with CD4 and SLAMF7, a surface marker we have previously described in CD4+CTLs (26) . Consistently, we observed a marked expansion of SLAMF7-expressing CD4+ T cells in SSc skin samples along with the coexpression of SLAMF7 and GZMA (Supplemental Figures 1A-C) . Because multiple reports 7 have associated T H2 cells with the pathogenesis of SSc, we first focused on the relative contribution of T H2 cells compared with CD4+CTLs and observed a striking preponderance of CD4+CTLs in contrast to the small proportions and absolute numbers of T H2 cells (Figures 2A-C) (11) (12) (13) (14) . Utilizing skin samples from patients with bullous pemphigoid, an established T H2mediated autoimmune skin disease, we compared the absolute numbers of CD4+CTLs and T H2 cells across our experimental groups (37) . Consistent with previous reports, T H2 Other CD4+ T cell subsets have also been implicated in the pathogenesis of SSc but comprehensive and quantitative analyses of tissues have not been previously reported (11) (12) (13) (14) 19) . In order to more comprehensively quantify all major CD4+ T cell subsets, including T H1 , T H2 , T H17 and T FH cells, as well as T regs and CD4+CTLs, we selected tissues from a subset of our patients, including a sampling of subjects with CD4+CTL numbers above, at and below the 
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We previously demonstrated an expanded tissue infiltrate dominated by CD4+CTLs in patients with IgG4-RD (26, 27) . Those cells express multiple pro-fibrotic and pro-inflammatory molecules at sites of disease. As in IgG4-RD, a subset of infiltrating CD4+CTLs in SSc tissues was found to actively express IL-1β (Supplemental Figures 4A-B) .
Given the prominent contribution of CD4+CTLs to the overall CD4+ T cell infiltrate and since the numbers of CD4+ and CD8+ T cells infiltrating SSc tissues were comparable, we sought to determine whether CD8+ T cells in the tissues were potentially cytotoxic. While on average, a greater proportion of CD8+ T cells (compared to CD4+ T cells) expressed GZMA, the absolute numbers of GZMA+ CD8+ T cells were similar to those of GZMA+ CD4+ T cells
Endothelial cells are frequent targets of apoptosis and upregulate HLA class II in SSc tissues
We previously observed the functional capacity for cytotoxicity by CD4+CTLs in in vitro co-culture experiments (26) . To explore the possibility of the cytotoxic targeting of host cells by tissue-infiltrating cytotoxic T cells, we quantified the number of cells undergoing apoptotic cell death using an antibody that recognizes cleaved caspase-3 (cCasp-3) ( Figure 4A ). Confirming previous reports associating tissue apoptosis with the pathogenesis of SSc, we observed a marked increase in the absolute number of apoptotic cells in SSc tissues compared to those of controls ( Figures 4B-C) . Often, the numbers of apoptotic cells found in tissues affected by SSc were quite prominent in the range of 50-100 apoptotic cells per high power field ( Figure 4C ).
Given the many previous reports describing, but not quantitating, endothelial cell apoptosis in SSc, we explored the origin of apoptotic cells in SSc tissues to provide a comprehensive tissue-based analysis and determine if endothelial cells were, in fact, prominent targets of apoptosis in this disease. We first co-stained for cCasp-3 and markers of major immune cell lineages and identified that the majority of apoptotic cells did not express CD19, 9 CD3 and CD68, indicating that very few macrophages and lymphoid cells undergo apoptosis in SSc skin ( Figure 4D ). Because observations such as nailfold capillary obliteration, digital ulceration, renal crisis, and anti-endothelial cell antibodies are all frequently associated with the vasculopathy of SSc but distinctly absent in the context of IgG4-RD, we used the latter disease as a source of control tissue samples to assess the preferential targeting of endothelial cells to undergo apoptosis in ex vivo tissue samples. Consistent with previous reports, we observed a striking and significant increase in the proportion of apoptotic cells accounted for by dying 
Analyses of CD4+CTL heterogeneity defines a specific subset relevant to SSc
To further characterize CD4+CTLs in the disease-specific context of SSc, we utilized blood samples from two different cohorts of SSc patients, including 14 from whom paired skin tissue samples were available and were included in the above tissue studies. Using our previous studies in IgG4-RD as a framework, we examined the phenotype of CD4+SLAMF7+ TEM cells based on surface CD28 and CD57 expression (26) . CD28 is a costimulatory receptor that is downregulated upon serial antigen recognition by the TCR (39) and CD57 is a poorlyunderstood sulfated glyco-epitope that has been associated with both T cell senescence and cytotoxicity (40, 41) . We found a large proportion of CD4+CTLs to have gained CD57 expression, with or without having lost CD28 expression (Supplemental Figure S7A ). CD57expressing CD4+CTLs were expanded in the blood of SSc patients with over 50% of the subjects demonstrating numbers above the vast majority of age-matched healthy donors ( Figure 6A ). We identified a trend towards significant correlation between these circulating cells and the presence of interstitial lung disease, and this provided some support for a pathologic role for CD57hi CD4+CTLs ( Figure 6B ). Moreover, from the subjects with paired blood and tissue samples, we observed circulating CD57hi CD4+CTLs to positively correlate with the extent of activated myofibroblasts within the paired skin samples ( Figure 6C ). Analyzing the SSc subjects with increased circulating CD57hi CD4+CTLs compared to those with normal levels, we found a correlation with increasing age (Supplemental Figure 7B ) but no correlation with gender, disease duration, auto-antibody profile, modified Rodnan skin score, the presence of digital ulceration or the presence of renal crisis.
Because CD57hi CD4+CTLs were composed of both CD28hi and CD28lo cells, and the CD28hiCD57lo subset of CD4+CTLs most often dominated the composition of CD4+CTLs from healthy donors (Supplemental Figure 7A) , we further phenotyped these respective subsets by additional surface and intra-cellular flow cytometry studies. Examining various effector molecules of cytotoxicity including GZMA, granzyme B (GZMB), and perforin (PRF), we found the CD28hiCD57lo CD4+CTLs to most closely resemble naïve CD4+ T cells, CD28loCD57hi
CD4+CTLs to most closely resemble CD8+CTLs and CD28hiCD57hi CD4+CTLs to have an intermediate phenotype ( Figure 6D, Supplemental Figure 7C ). Consistent with the idea of progressive differentiation from a precursor to an effector phenotype of CD4+CTLs, the CD28loCD57hi subset expressed the greatest amount of CX3CR1, a marker previously associated with effector CD4+CTLs and protective anti-viral immunity whereas the CD28hiCD57lo subset expressed the greatest amount of CD127 (IL7R), which was previously reported as a surface marker of precursor CD4+CTLs ( Figure 6D ) (34, 42) . Focusing on the CD4+CTL subset with the strongest effector phenotype, we performed TCR repertoire analysis on CD28loCD57hi CD4+CTLs sorted from the blood of SSc patients and observed marked clonal expansion of effector CD4+CTLs compared to their naïve CD4+ T cell counterparts with 1-2 clones dominating the TCR repertoire and representing 50-75% of all sequence reads ( Figure 6E ).
The transcriptome of CD28loCD57hi CD4+CTLs is enriched by genes relevant to cytotoxicity, metabolic activity and tissue remodeling
Following the above observations supporting the notion that CD4+SLAMF7+ T EM cells that have lost CD28 and gained CD57 expression represent the most differentiated effector subset of CD4+CTLs, we sought to characterize the transcriptional features of this cell population in order to make inferences about its functional role in the pathogenesis of SSc. We sorted CD4+ naïve T cells and CD28loCD57hi CD4+CTLs from the blood of 3 SSc patients and performed whole transcriptome RNA sequencing. We searched for biologically meaningful transcriptional signatures using gene set enrichment analysis and compared effector CD4+CTLs to naïve CD4+ T cells in order to have the broadest comprehension of the CD28loCD57hi CD4+CTL transcriptome. As an exploratory analysis, we first used the CIBERSORT gene set database to suggest the cellular phenotype of the sorted CD4+CTLs. In addition to gene sets available through CIBERSORT, we also included two curated gene sets representing the CD4+CTL transcriptome based on available transcriptome data (26, 34) . This validated our sorting strategy by confirming a cytotoxic phenotype of CD28loCD57hi CD4+CTLs, which are transcriptionally more similar to γδ T cells and CD8+CTLs than to traditional CD4+ T cells ( Figure 7A) . Based on the strongest enrichment observed with the CD4+CTL curated gene lists, these cells have a distinctly different transcriptional signature compared with all other cytotoxic cell types, such as γδ T cells, CD8+CTLs and NK cells, suggesting that they may play To explore biological pathways that may be relevant to CD28loCD57hi CD4+CTLs, we examined enrichment among the Reactome gene set database. We identified gene expression in CD28loCD57hi CD4+CTLs to be linked to gene sets that suggest these cells are poised for survival (upregulated KRAS signaling, MYC target genes) and have a metabolically active 13 phenotype (upregulated mTORC1, oxidative phosphorylation) (Supplemental Figure 9 ). We also observed transcriptomic evidence that CD28loCD57hi CD4+CTLs are conditioned by type I and type II interferons, both of which have been implicated in the pathogenesis of systemic sclerosis (43) (44) (45) . Overall, these findings are consistent with the notion that CD28loCD57hi
CD4+CTLs represent an activated effector population of CD4+ T cells involved in the ongoing immune response at the time of sample collection rather than a resting memory or exhausted T cell population.
Ongoing T cell activation may be a feature of early diffuse systemic sclerosis
CTLA4-Ig (Abatacept) has the ability to block the interaction of CD28 on naïve T cells with CD80 and CD86 on antigen presenting cells. The above blood studies from SSc patient samples suggest the progressive differentiation of CD4+CTLs from a precursor population, to an intermediate subset marked by the gain of CD57 expression and finally to a fully differentiated effector subset that has gained CD57 and lost CD28 expression. In addition to these two CD28 expressing CD4+CTL subsets that may give rise to CD28loCD57hi CD4+CTLs, effector T cells are likely being generated frequently in lymph nodes from naïve or memory CD28-expressing T cells in the setting of ongoing disease activity following the presentation of self-antigens that have been captured by dendritic cells. In this context, it is plausible that CTLA4-Ig treatment may block the differentiation of naïve CD4+ T cells, memory CD4+ T cells and precursor subsets of CD4+CTLs into bona fide effector CD4+CTLs through interference with co-stimulation. To explore this, we examined pre-and post-treatment skin biopsies of four patients with early diffuse SSc who were enrolled in the ASSET trial examining the efficacy of CTLA4-Ig in SSc (46) . We noted a discernible decline in tissue infiltrating CD4+CTLs in 3 of the 4 patients (Supplemental Figure 10) . Ongoing T cell activation appears to be a feature of early 14 diffuse SSc and there is therefore a rationale for targeting patients early in this disease with interventions that prevent T cell activation or attenuate T cell cytotoxicity.
Discussion
Using quantitative approaches to examine a range of infiltrating cells we have identified GZMA-expressing CD8+ T cells and CD4+CTLs as the most prominent T cells in SSc lesions.
Quantitative analyses of immune cells in SSc tissues have not been undertaken previously, and our findings have attempted to elucidate the relevance of T cells, including several CD4+ T cell subsets, in this disease. T H2 and T FH cells were found to infiltrate tissues only in low numbers in our studies. In contrast, CD4+CTLs infiltrate SSc skin in high numbers, with expansions seen in nearly 80% of cases when compared to healthy donor tissues. In some subjects, an increase in T H17 cells was noted, but even in these biopsies the majority of infiltrating T cells are cells with the potential for cytotoxicity when considering both CD4+CTLs and CD8+ T cells.
Apart from inducing apoptosis, CD4+CTLs cells are known to secrete pro-fibrotic as well as pro-inflammatory cytokines, including TGFβ and IL-1β. These cytokines may directly contribute to local tissue remodeling processes (26, 27) . We observed the expression of IL-1β in CD4+CTLs at the site of disease in SSc tissues, supporting a pro-inflammatory and/or profibrotic function of these cells in addition to a cytotoxic one.
Our current studies have identified a large number of apoptotic cells within the tissues of patients with SSc, concomitant with the accumulation of both CD8+CTLs and CD4+CTLs, indirectly implicates these cytotoxic T cells in the targeted killing of host cells (26) . We quantified the number of apoptotic cells in samples from patients finding median values of approximately 100 cCasp-3 positive cells per mm 2 in SSc compared to control tissues with < 15 apoptotic cells per mm 2 . Consistent with the prominent vasculopathy that precedes and then progresses concurrently with tissue fibrosis in SSc, we found endothelial cells to be a frequent target of apoptosis in SSc biopsies. Moreover, many endothelial cells in the SSc skin samples expressed HLA class II molecules. Collectively, these findings support the view that CD4+CTLs and CD8+ T cells in SSc may contribute to vasculopathy and tissue fibrosis by targeted endothelial cell killing and by the elaboration of pro-inflammatory molecules such as IL-1β, leading to overly exuberant tissue remodeling.
Apoptosis of endothelial cells in SSc tissues has been noted for decades (47) . While anti-endothelial cell antibodies capable of inducing apoptosis of endothelial cells have been frequently reported, tissue studies precisely cataloguing the cell types undergoing apoptosis, or quantifying apoptotic cells have not previously been undertaken (48) (49) (50) (51) (52) . We have observed that endothelial cells undergoing apoptosis are often in close proximity to cytotoxic T cells and sometimes can even be seen to have acquired GZMA in the cytosol. Future studies involving multi-color confocal microscopy on thick frozen sections of SSc biopsies and the use of cell distance mapping may provide further correlations about the potential physical interactions between cytotoxic T cells and endothelial cells in this disease.
The definitive identification of self-antigens that are recognized by expanded T cell clones that infiltrate tissues in SSc patients would strengthen the view that self-reactive T cells drive this disease process. It is likely that certain relevant host proteins expressed at relatively high levels in endothelial cells contribute peptides that are presented on HLA class I molecules and that a distinct or overlapping subset of proteins yields peptides that are presented by HLA class II molecules. These antigens may come into play following a break in peripheral T cell tolerance and they presumably initiate immune responses in draining lymph nodes. Activated effector CD4+ and CD8+ cytotoxic T cells may then target host cells, particularly endothelial cells, in SSc tissues. The centromeric CENP-A and CENP-B proteins and the interferoninducible 16 protein (IFI-16), known antigens recognized by auto-antibodies in SSc, have been found to be expressed at relatively high levels in endothelial cells (53) . Whether or not peptides from these antigens are presented on HLA molecules for T cell recognition and thus contribute to T cell mediated endothelial cell apoptosis remains to be established.
Our studies quantitatively establish that the accumulation in the skin of CD4+CTLs and
CD8+CTLs is a hallmark of early diffuse systemic sclerosis and suggest that similar quantitative tissue studies should be undertaken in other inflammatory diseases of the skin including disorders in which fibrosis is not a dominant feature. We have previously noted that CD4+CTLs accumulate in affected tissues in another fibrotic disease, IgG4-RD, but not in two non-fibrotic disorders, chronic sialadenitis and Sjögren's syndrome (26, 27) . While our results provide a potential mechanism for the long-described phenomenon of endothelial cell apoptosis in this disease, we also note that there is a general increase in apoptosis even in non-endothelial cells in SSc biopsies in comparison to normal skin. While fibrosis is generally considered to be linked to inflammatory cytokines, apoptotic cells have been shown to trigger TAM family kinases on macrophages and thus accelerate wound healing (54) . Apoptotic death in the lung resulting from germline mutations has also been postulated to contribute to the fibrotic process in idiopathic pulmonary fibrosis (55) . Our data support the view that cytotoxic T cells may contribute to a fibrotic disease by both inducing apoptosis and secreting pro-fibrotic cytokines.
An overview model for the pathogenesis of systemic sclerosis based on our observations is presented in Figure 8 .
It is likely that in active SSc, there is ongoing presentation of antigen to naïve CD4+ and CD8+ T cells and the recurrent activation of these cells in secondary lymphoid organs. The decline in CD4+CTLs after treatment with CTLA-Ig is consistent with such a view. It is therefore likely that interventions targeting cytotoxic T cells early in this disease may potentially halt the progression of this therapeutically intractable disease.
Methods
Patient Cohorts:
Skin tissue (n = 35) and blood (n = 28) samples from SSc subjects and skin tissue samples from healthy donors (n = 10) were obtained through a collaboration with the NIH- 
Multi-color immunofluorescence staining:
Tissue samples were fixed in formalin, embedded in paraffin, and sectioned. These performed, analyzed and scored using a 10-cm visual analog scale, as previously described (56) .
Microscopy and Quantitative Image Analysis:
Images of the tissue specimens were acquired using the TissueFAXS platform (TissueGnostics). For quantitative analysis, the entire area of the tissue was acquired as digital grayscale images in five channels with filter settings for FITC, Cy3, Cy5 and AF75 in addition to DAPI. Cells of a given phenotype were identified and quantitated using the TissueQuest software (TissueGnostics), with cut-off values determined relative to the positive controls. This microscopy-based multicolor tissue cytometry software permits multicolor analysis of single cells within tissue sections similar to flow cytometry. The principle of the method and the algorithms used have been described in detail elsewhere (57) . Myofibroblast activation was graded within tissues by the alpha smooth muscle actin score, as previously described (56) .
FACS-sorting, Bulk RNA Sequencing & TCR Repertoire Studies:
Frozen PBMC were thawed, washed and stained with the same antibody panel as used for flow cytometry experiments, above. Consistent with our flow cytometry studies, effector
CD4+CTLs were sorted based on the following gates: CD3+ CD4+ CD8-CCR7-CD45RA-SLAMF7+ CD28lo CD57hi. CD4+ naïve T cells were sorted based on the following gates: CD3+ CD4+ CD8-CCR7+ CD45RA+. Cells were sorted directly into 350 uL RLT-BME lysis buffer, vortexed briefly and immediately frozen on dry ice. Cells were sorted on a FACSAria II with FACSDiva version 7. RNA was isolated from sorted cell lysates using RNeasy Plus Micro Kits (Qiagen, 74034). For bulk RNA sequencing, isolated RNA was immediately processed through RT-PCR, as previously described (58) . For TCR repertoire, isolated RNA was immediately processed through 5'RACE RT-PCR, as previously described (59, 60) . Sequence data was deposited into the GEO repository. The accession number is GSE142663.
Statistics:
Flow cytometry, clinical correlations and tissue studies. A p-value of < 0.05 was considered significant.
Bulk RNA-sequencing. Raw FASTA files (read 1 and read 2) were processed with the zUMIs v2.2 pipeline using the splice-aware aligner STAR v2.5.4a, SAMtools v1.9 and pigz v2.3.4 (61) . In short, reads were filtered according a predefined list matching the custom-made well barcodes in the oligo-dTs and unique molecular identifiers were then collapsed. The remaining reads were mapped to the reference genome with use of the STAR aligner. Exon
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counts from mapped reads were imported into R studio v1.1.456 and further processed for statistical analysis with DESeq2 v1.22.1. Since we compare multiple cellular subtypes per patient, we controlled for between patient variability in the design matrix. Fitting of the models' dispersion to the mean intensity was performed with local regression and the effect sizes were Clonotype abundances were calculated by CDR3 nucleotide, V and J matching among CD4+
CTLs.
Study Approval:
These studies were approved by the Institutional Review Boards at the Massachusetts Analyzing CD28loCD57hi CD4+CTLs to naïve CD4+ T cells, we iden*fied enrichment for many gene sets, including A) alignment with previously reported CD4+CTL transcriptomes and greater similarity with γδ T cell and CD8+ T cell transcriptomes rather than with conven*onal CD4+ T cells and B) those associated with fibrogenesis such as regula*on of fibroblast apoptosis, regula*on of endothelial cell migra*on and hemostasis. Size of dots represents number of genes within a given gene set. X-axes represent the % of genes within a gene set enriched for by the effector CD4+CTL transcriptome. C) CNET plot showing all genes upregulated by effector CD4+CTLs from immune cell transcrip*onal gene sets showing a prominent cytotoxic profile with upregula*on of GZMA, GZMB, GZMM, GZMH, PRF1 and SLAMF7. fgsea version 1.12.0 was used to calculate all p-values. 
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